A Study to Evaluate the Safety and Effectiveness of Eye Drops for Those Suffering from Eye Disease Following Bone Marrow Transplantation

Official Title: A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients with ocular Graft-vs-Host Disease (oGVHD)


The purpose of this study is to test how well an eye drop works at relieving severe symptoms of ocular graft vs. host disease. You may have oGVHD if you had a bone marrow transplant and experience blurry vision, light sensitivity, dry eye, eye pain, and eye redness. This study will require you to use the eye drop twice daily for a period of 12 weeks. You will not be asked to stop your current eye medications or treatments.

Eligibility criteria:

-Recipient of a bone marrow transplant (or allogeneic hematopoietic stem cell transplant)
-Stable use of medications (no changes) for the last 30 days
-Not allergic to brimonidine or currently receiving it as treatment for glaucoma
-Not pregnant or currently lactating
-Meet additional study criteria

Contact Information

Jessica Barger, Alana Monzon